TN2014000345A1 - Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative - Google Patents

Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative

Info

Publication number
TN2014000345A1
TN2014000345A1 TNP2014000345A TN2014000345A TN2014000345A1 TN 2014000345 A1 TN2014000345 A1 TN 2014000345A1 TN P2014000345 A TNP2014000345 A TN P2014000345A TN 2014000345 A TN2014000345 A TN 2014000345A TN 2014000345 A1 TN2014000345 A1 TN 2014000345A1
Authority
TN
Tunisia
Prior art keywords
pharmaceutical preparation
preparation containing
antivirally active
dihydroquinazoline derivative
dihydroquinazoline
Prior art date
Application number
TNP2014000345A
Other languages
English (en)
Inventor
Kerstin Paulus
Wilfried Schwab
Dominique Grunder
Hoogevest Peter Van
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47757622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2014000345(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of TN2014000345A1 publication Critical patent/TN2014000345A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TNP2014000345A 2012-02-29 2014-08-08 Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative TN2014000345A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102012101680A DE102012101680A1 (de) 2012-02-29 2012-02-29 Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
PCT/EP2013/054114 WO2013127970A1 (fr) 2012-02-29 2013-02-28 Préparation pharmaceutique contenant un dérivé de dihydrochinazoline à action antivirale

Publications (1)

Publication Number Publication Date
TN2014000345A1 true TN2014000345A1 (en) 2015-12-21

Family

ID=47757622

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2014000345A TN2014000345A1 (en) 2012-02-29 2014-08-08 Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative

Country Status (37)

Country Link
US (1) US10603384B2 (fr)
EP (3) EP2819648B1 (fr)
JP (1) JP6387486B2 (fr)
KR (1) KR102149561B1 (fr)
CN (2) CN104144678A (fr)
AU (1) AU2013224947B2 (fr)
BR (1) BR112014020946B1 (fr)
CA (1) CA2865203C (fr)
CL (1) CL2014002306A1 (fr)
CO (1) CO7061076A2 (fr)
CY (1) CY1121910T1 (fr)
DE (1) DE102012101680A1 (fr)
DK (2) DK3556350T3 (fr)
EA (1) EA026584B1 (fr)
ES (2) ES2741698T3 (fr)
FI (1) FI3556350T3 (fr)
HK (1) HK1205462A1 (fr)
HR (2) HRP20240197T1 (fr)
HU (2) HUE045949T2 (fr)
IL (1) IL234363B (fr)
IN (1) IN2014MN01892A (fr)
LT (2) LT3556350T (fr)
MA (1) MA35941B1 (fr)
ME (1) ME03448B (fr)
MX (1) MX369666B (fr)
MY (1) MY172310A (fr)
NZ (1) NZ628444A (fr)
PH (1) PH12014501937A1 (fr)
PL (2) PL3556350T3 (fr)
PT (2) PT2819648T (fr)
RS (2) RS65137B1 (fr)
SG (1) SG11201405294XA (fr)
SI (2) SI3556350T1 (fr)
TN (1) TN2014000345A1 (fr)
UA (1) UA111415C2 (fr)
WO (1) WO2013127970A1 (fr)
ZA (1) ZA201405949B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) * 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
SG11201510426PA (en) * 2013-06-19 2016-01-28 Aicuris Anti Infective Cures Gmbh Amorphous letermovir and solid pharmaceutical formulations thereof for oral administration
EP3463064B1 (fr) 2016-06-03 2021-11-03 Atreya Innovations Private Limited Dispositif pour la détection et la capture fiable des caractéristiques de pouls
WO2018165048A1 (fr) 2017-03-06 2018-09-13 VenatoRx Pharmaceuticals, Inc. Formes solides et compositions de combinaison comprenant un inhibiteur de bêta-lactamase et leurs utilisations
UY39099A (es) * 2020-02-27 2021-08-31 Aic246 Gmbh & Co Kg 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio y composiciones farmacéuticas del mismo
UY39095A (es) * 2020-02-27 2021-09-30 Aic246 Gmbh & Co Kg Composiciones farmacéuticas que comprenden acetato de 2- [(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio
CN114539085B (zh) * 2020-11-26 2023-10-20 山东诚创蓝海医药科技有限公司 一种脲基衍生物的制备
CN115403528A (zh) * 2021-05-27 2022-11-29 南京正大天晴制药有限公司 无定形3,4-二氢喹唑啉衍生物的制备方法
CN113880776B (zh) * 2021-11-16 2023-06-16 山东诚创蓝海医药科技有限公司 一种莱特莫韦中间体的制备方法
AR128035A1 (es) 2021-12-21 2024-03-20 Aic246 Ag & Co Kg Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de potasio
CN115322157B (zh) * 2022-06-02 2023-12-05 浙江车头制药股份有限公司 来特莫韦中间体化合物及其制备方法和应用
CN115677539B (zh) * 2022-11-01 2023-10-24 南京工业大学 一种温和条件下钴催化脲基导向芳烃的高选择性单烯基化的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1242699A (fr) * 1985-02-01 1988-10-04 Bristol-Myers Company Cefbuperazone et ses derives
CA1284994C (fr) * 1985-08-05 1991-06-18 Murray Arthur Kaplan Sels de cephalosporine, et compositions injectables
JP3552240B2 (ja) * 1993-02-23 2004-08-11 第一製薬株式会社 高濃度tcf製剤
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
IT1304190B1 (it) * 1998-12-18 2001-03-08 Euphar Group Srl Clatrati di deidroepiandrosterone e relative composizionifarmaceutiche
PL200804B1 (pl) * 1999-03-17 2009-02-27 Astrazeneca Ab Pochodne amidowe, sposoby ich wytwarzania, ich kompozycje farmaceutyczne oraz ich zastosowanie
AU2000249111A1 (en) * 2000-05-30 2001-12-11 Dr. Reddy's Research Foundation New pharmaceutical composition and the process for its preparation
DE10319612A1 (de) * 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
WO2005051922A1 (fr) * 2003-11-25 2005-06-09 Chiron Corporation Composes quinazolinone utilises en tant qu'agents anticancereux
WO2006086464A2 (fr) 2005-02-10 2006-08-17 Bristol-Myers Squibb Company Dihydroquinazolinones utilisees comme modulateurs de la 5ht
DE102005027517A1 (de) 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
US8743287B2 (en) * 2009-07-24 2014-06-03 Broadcom Corporation Method and system for mitigating motion trail artifacts and improving low contrast contours in temporal filtering based noise reduction

Also Published As

Publication number Publication date
EP3556350A1 (fr) 2019-10-23
SI2819648T1 (sl) 2019-10-30
EP2819648A1 (fr) 2015-01-07
RS65137B1 (sr) 2024-02-29
KR102149561B1 (ko) 2020-08-31
ME03448B (fr) 2020-01-20
JP2015508801A (ja) 2015-03-23
SI3556350T1 (sl) 2024-03-29
MX369666B (es) 2019-11-14
NZ628444A (en) 2016-07-29
EA026584B1 (ru) 2017-04-28
RS59157B1 (sr) 2019-10-31
PL3556350T3 (pl) 2024-05-06
US20150133461A1 (en) 2015-05-14
CA2865203C (fr) 2019-11-05
US10603384B2 (en) 2020-03-31
HUE065553T2 (hu) 2024-06-28
PT2819648T (pt) 2019-09-05
WO2013127970A1 (fr) 2013-09-06
BR112014020946B1 (pt) 2022-04-05
BR112014020946A2 (fr) 2017-06-20
DE102012101680A1 (de) 2013-08-29
ZA201405949B (en) 2021-07-28
EP4328218A2 (fr) 2024-02-28
MY172310A (en) 2019-11-21
JP6387486B2 (ja) 2018-09-12
CN110433166A (zh) 2019-11-12
CL2014002306A1 (es) 2014-11-28
HRP20240197T1 (hr) 2024-04-26
ES2741698T3 (es) 2020-02-12
PH12014501937A1 (en) 2014-11-24
IN2014MN01892A (fr) 2015-07-10
ES2972133T3 (es) 2024-06-11
DK3556350T3 (da) 2024-02-12
MX2014010364A (es) 2014-12-05
EP4328218A3 (fr) 2024-04-10
PL2819648T3 (pl) 2019-10-31
CN104144678A (zh) 2014-11-12
UA111415C2 (uk) 2016-04-25
LT3556350T (lt) 2024-02-26
KR20140130683A (ko) 2014-11-11
HK1205462A1 (en) 2015-12-18
AU2013224947B2 (en) 2017-06-29
LT2819648T (lt) 2019-09-10
PT3556350T (pt) 2024-02-15
DK2819648T3 (da) 2019-08-26
HRP20191369T1 (hr) 2019-11-01
MA35941B1 (fr) 2014-12-01
CY1121910T1 (el) 2020-10-14
EP3556350B1 (fr) 2024-01-10
IL234363B (en) 2020-04-30
SG11201405294XA (en) 2014-11-27
EA201400963A1 (ru) 2015-02-27
AU2013224947A1 (en) 2014-09-18
FI3556350T3 (fi) 2024-02-14
CO7061076A2 (es) 2014-09-19
HUE045949T2 (hu) 2020-01-28
EP2819648B1 (fr) 2019-05-29
CA2865203A1 (fr) 2013-09-06

Similar Documents

Publication Publication Date Title
TN2014000345A1 (en) Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative
CY1120832T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
WO2014205389A8 (fr) Modulateurs de transport nucléaire et leurs utilisations
PH12015501964A1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
WO2014028589A3 (fr) Composés d'acide benzoïque substitués par un 4-hétéroaryle à titre d'inhibiteurs de rorgammat et leurs utilisations
WO2011127333A3 (fr) Composés pour le traitement d'une maladie, pour l'administration, et pour des compositions pharmaceutiques
BR112015000704A2 (pt) imidazotriazinacarbonitrilas úteis como inibidores de quinase
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
WO2014076569A3 (fr) Formulations de testostérone topiques à libération commandée et procédés associés
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
WO2013061004A8 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
WO2012162439A3 (fr) Compositions comprenant de l'acide fusidique et leurs emballages
MX357888B (es) Sales basicas de adicion de nitroxolina y usos de las mismas.
BR112014021497A2 (pt) sistema de entrega de fármaco baseado em jcv-vlp
GEP20156332B (en) Pyrazoles as crth2 antagonists
PH12015502717A1 (en) Anti-fibrogenic compounds, methods and uses thereof
WO2014104989A8 (fr) Compositions pharmaceutiques comprenant de l'aripiprazole
WO2012123924A3 (fr) Composition antimicrobienne
TR201203086A2 (tr) Sefiksim ve klavulanik asit içeren farmasötik dozaj formu.